Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination

Jo Anne H. Young

doi:10.1016/j.jtct.2021.08.003

Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination

Jo Anne H. Young

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	700-701
Number of pages	2
Journal	Transplantation and Cellular Therapy
Volume	27
Issue number	9
DOIs	https://doi.org/10.1016/j.jtct.2021.08.003
State	Published - Sep 2021

Bibliographical note

Funding Information:
J.H.Y. is a co-investigator for the Center for International Blood and Marrow Transplant Research study under ClinicalTrials.gov identifier NCT01166009. J.H.Y. reports that The University of Minnesota is paid on a per-subject basis to cover the costs of enrolling subjects on clinical trials unrelated to coronavirus infections, for AlloVir, Astellas, Ansun, Cidara, Janssen, Merck, NobelPharma, ReViral, Scynexis, and Shire/Takeda, outside the submitted work.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/j.jtct.2021.08.003

Find It

Find It at U of M Libraries

Cite this

@article{beff26bedce44ad48d01a41b18e37208,

title = "Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination",

author = "Young, \{Jo Anne H.\}",

note = "Funding Information: J.H.Y. is a co-investigator for the Center for International Blood and Marrow Transplant Research study under ClinicalTrials.gov identifier NCT01166009. J.H.Y. reports that The University of Minnesota is paid on a per-subject basis to cover the costs of enrolling subjects on clinical trials unrelated to coronavirus infections, for AlloVir, Astellas, Ansun, Cidara, Janssen, Merck, NobelPharma, ReViral, Scynexis, and Shire/Takeda, outside the submitted work.",

year = "2021",

month = sep,

doi = "10.1016/j.jtct.2021.08.003",

language = "English (US)",

volume = "27",

pages = "700--701",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier B.V.",

number = "9",

}

TY - JOUR

T1 - Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination

AU - Young, Jo Anne H.

N1 - Funding Information: J.H.Y. is a co-investigator for the Center for International Blood and Marrow Transplant Research study under ClinicalTrials.gov identifier NCT01166009. J.H.Y. reports that The University of Minnesota is paid on a per-subject basis to cover the costs of enrolling subjects on clinical trials unrelated to coronavirus infections, for AlloVir, Astellas, Ansun, Cidara, Janssen, Merck, NobelPharma, ReViral, Scynexis, and Shire/Takeda, outside the submitted work.

PY - 2021/9

Y1 - 2021/9

UR - https://www.scopus.com/pages/publications/85115347396

UR - https://www.scopus.com/pages/publications/85115347396#tab=citedBy

U2 - 10.1016/j.jtct.2021.08.003

DO - 10.1016/j.jtct.2021.08.003

M3 - Comment/debate

C2 - 34452720

AN - SCOPUS:85115347396

SN - 2666-6367

VL - 27

SP - 700

EP - 701

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 9

ER -

Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this